Dept. of Biochemistry and Molecular Biology, Univ. of Texas Medical Branch, Galveston, 77555, USA.
Am J Physiol Heart Circ Physiol. 2010 Apr;298(4):H1198-208. doi: 10.1152/ajpheart.00915.2009. Epub 2010 Jan 22.
Phosphoinositide 3-kinase (PI3K) mediates myocardium protective signaling through phosphorylation of phosphatidylinositol (Ptdins) to produce Ptdins(3,4,5)P(3). Lipid phosphatase and tensin homolog on chromosome 10 (PTEN) antagonizes PI3K activity by dephosphorylating Ptdins(3,4,5)P(3); therefore, the inhibition of PTEN enhances PI3K/Akt signaling and could prevent myocardium from ischemia-reperfusion (I/R) injury. Here we studied 1) whether the pharmacological inhibition of PTEN by bisperoxovanadium molecules [BpV(HOpic)] attenuates simulated I/R (SIR) injury in vitro and 2) whether the administration of BpV(HOpic) either before or after ischemia limits myocardial infarct size (IS) and ameliorates cardiodysfunction caused by infarction. First, adult rat cardiomyocytes were treated with or without BpV(HOpic) and then exposure to SIR. Second, anesthetized rats received BpV(HOpic) either before or after ischemia. IS was assessed at 4 h reperfusion, and left ventricular function was evaluated by echocardiography at 28 days postreperfusion. As a result, BpV(HOpic) decreased cell death, improved 3-[4,5-yl]-2,5-diphenyltetrazolium bromide (MTT) viability, and reduced apoptosis in cells exposed to SIR. These protective effects of BpV(HOpic) are associated with increased phospho-Akt and the repression of caspase-3 activity. Second, the administration of BpV(HOpic) significantly reduced IS and suppressed caspase-3 activity following I/R injury and consequentially improved cardiac function at 28 day postinfarction. These beneficial effects of BpV(HOpic) are attributed to increases in myocardial levels of phosphorylation of Akt/endothelial nitric oxide synthase (eNOS), ERK-1/2, and calcium-dependent nitric oxide synthase activity. In conclusion, the pharmacological inhibition of PTEN protects against I/R injury through the upregulation of the PI3K/Akt/eNOS/ERK prosurvival pathway, suggesting a new therapeutic strategy to combat I/R injury.
磷酸肌醇 3-激酶 (PI3K) 通过磷酸化磷脂酰肌醇 (PtdIns) 产生 PtdIns(3,4,5)P(3),从而介导心肌保护信号。染色体 10 上的油酰胺磷酸酶和张力蛋白同源物 (PTEN) 通过去磷酸化 PtdIns(3,4,5)P(3)拮抗 PI3K 活性;因此,PTEN 的抑制增强了 PI3K/Akt 信号转导,并可防止心肌缺血再灌注 (I/R) 损伤。在这里,我们研究了 1)双过氧钒分子 [BpV(HOpic)] 对体外模拟 I/R (SIR) 损伤的药理学抑制作用,2)缺血前或缺血后给予 BpV(HOpic) 是否限制心肌梗死面积 (IS) 并改善梗塞引起的心功能障碍。首先,用或不用 BpV(HOpic) 处理成年大鼠心肌细胞,然后暴露于 SIR。其次,麻醉大鼠在缺血前或缺血后接受 BpV(HOpic)。在再灌注 4 小时评估 IS,并在再灌注后 28 天通过超声心动图评估左心室功能。结果,BpV(HOpic)减少了细胞死亡,提高了 3-[4,5-yl]-2,5-diphenyltetrazolium bromide (MTT) 活力,并降低了 SIR 暴露细胞的凋亡。BpV(HOpic) 的这些保护作用与磷酸化 Akt 的增加和 caspase-3 活性的抑制有关。其次,BpV(HOpic)的给药显著降低了 I/R 损伤后的 IS,并抑制了 caspase-3 活性,进而在梗塞后 28 天改善了心脏功能。BpV(HOpic) 的这些有益作用归因于心肌中 Akt/内皮型一氧化氮合酶 (eNOS)、ERK-1/2 和钙依赖性一氧化氮合酶活性的磷酸化增加。总之,PTEN 的药理学抑制通过上调 PI3K/Akt/eNOS/ERK 生存途径来保护免受 I/R 损伤,为对抗 I/R 损伤提供了一种新的治疗策略。